MDxHealth SA MDXH
At closeNov 3, 2026, 7:51 PM EST
After hours · Nov 3, 7:51 PM ET
- YTD
- -95.56%
- 1 year
- -96.73%
- Market cap
- 15.11M
- Revenue (ttm)
- 84.71M
- Profit margin
- -49.52%
- EPS (ttm)
- -0.70
- Shares out
- 49.50M
- Forward P/E
- -3.81
- YTD return
- -95.56%
- 1-year return
- -96.73%
- Volume
- 192.72K
- Avg volume
- 6.21M
- Open
- 0.1605
- Previous close
- 0.157
- Day's range
- 0.1579 – 0.1672
- 52-week range
- 0.153 – 4.87
- Beta
- -393982.88
- Price target
- 6.04 (+3713.1%)
- Earnings date
- Nov 8, 2023
3M -0.2820 (-63.80%)
Key statistics
- Enterprise value
- 69.28M
- PEG ratio
- 0.00
- Price / sales
- 1.27
- Price / book
- 3.57
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 20.50%
- Free cash flow
- 5.11M
- Total cash
- 49.27M
- Total debt
- 55.34M
- Return on equity
- -240.82%
- Short % of float
- 0.10%
- 50-day average
- 2.02
- 200-day average
- 2.50
Analyst view
- Target (low)
- 4.20
- Target (mean)
- 6.04
- Target (high)
- 7.00
- Strong buy1
- Buy5
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 8, 2023
Expected Nov 8, 2023. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 6, 2024 | Sep 1, 2024 | -0.27 | -0.40 | -0.13 | -48.15% |
| Aug 21, 2024 | Jun 1, 2024 | -0.26 | -0.31 | -0.05 | -19.23% |
| May 1, 2024 | Mar 1, 2024 | -0.30 | -0.31 | -0.01 | -3.33% |
| Mar 6, 2024 | Dec 1, 2023 | 0.00 | -0.39 | — | — |
| Nov 8, 2023 | Sep 1, 2023 | -0.31 | — | — | — |
| Aug 23, 2023 | Jun 1, 2023 | -0.32 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 7, 2024 | Piper Sandler | main | Overweight | Overweight |
| Oct 31, 2024 | Lake Street | init | — | Buy |
| Mar 7, 2024 | Piper Sandler | main | Overweight | Overweight |
| Mar 7, 2024 | BTIG | main | Buy | Buy |
About MDxHealth SA
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection. The company offers genomic prostate score which provides personalized genomic insights to both physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. It sells its products through urology sales force, consisting of direct sales representatives, strategic account managers, and regional sales managers. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Country
- Belgium
- Website
- mdxhealth.com
News
Mdxhealth to Release Third Quarter 2026 Financial Results on November 12 
This Ameriprise Financial Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday 
Crude Oil Jumps 3%; Citizens Financial Earnings Top Views 
12 Health Care Stocks Moving In Friday's Intraday Session 
Dow Surges 250 Points; M&T Bank Posts Upbeat Q3 Earnings - 12 Health Care Stocks Moving In Friday's Pre-Market Session
Why Alcoa Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket 
12 Health Care Stocks Moving In Thursday's After-Market Session 
MDxHealth Announces Preliminary Third Quarter 2026 Revenue and Suspends Full-Year 2026 Revenue Guidance 
12 Health Care Stocks Moving In Wednesday's After-Market Session
Your note
Sign in to keep a note on MDXH — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| MVM PARTNERS LLP | Beneficial Owner of more than 10% of a Class of Security | Purchase | Feb 2, 2023 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Bleichroeder LP | 30.70% | 8,378,333 | 18.18M | Sep 29, 2024 |
| MVM Partners, LLC | 17.23% | 4,700,457 | 10.20M | Sep 29, 2024 |
| AWM Investment Company, Inc. | 15.57% | 4,250,000 | 9.22M | Sep 29, 2024 |
| Soleus Capital Management, L.P. | 4.05% | 1,105,000 | 2.40M | Sep 29, 2024 |
| Alyeska Investment Group, L.p. | 3.69% | 1,007,000 | 2.19M | Sep 29, 2024 |
| Monashee Investment Management LLC | 3.66% | 1,000,000 | 2.17M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| World Funds Tr-Perkins Discovery Fund | 0.13% | 35,000 | 75.95K | Sep 29, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.02% | 5,263 | 11.42K | Oct 30, 2024 |
| Brighthouse Fds Tr II-BH/Dimensional International Small Co Port | 0.00% | 843 | 1.83K | Sep 29, 2024 |